Using cell and gene therapy to treat neuroendocrine tumors
Official title: Allogeneic cell and gene therapy for neuroendocrine tumors
Funded at Expression Therapeutics · NIH-11066857 · Data updated 2026-11-12
This study is testing new treatments using donor cells to help fight rare neuroendocrine tumors, aiming to see how safe and effective these therapies are for patients who don’t have many options right now.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Expression Therapeutics NIH-funded |
| Lab location | 1 site (Tucker, United States) |
| Project start | December 4, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 1R43CA291373-01A1 |
| Project ID | NIH-11066857 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neuroendocrine tumors who have not responded adequately to existing therapies.
✕Less likely to help
Patients with localized, surgically removable neuroendocrine tumors may not benefit from this research as they might be better suited for surgical intervention.
What this research studies
This research focuses on developing innovative cell and gene therapies specifically for neuroendocrine tumors (NETs), which are rare cancers originating from neuroendocrine cells. The approach involves utilizing allogeneic cells, which are derived from a donor, to target and potentially eliminate tumor cells. Patients may receive these therapies through injections or infusions, and the research aims to assess the safety and effectiveness of these treatments in managing NETs. By leveraging advanced techniques in cell therapy, the study seeks to improve outcomes for patients who currently have limited treatment options.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with neuroendocrine tumors, potentially improving survival rates and quality of life.
How similar studies have gone: While the use of cell and gene therapies is a growing field, this specific approach for neuroendocrine tumors is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Expression Therapeutics
Tucker, United States Active
Researchers
- Principal investigator: Petrich, Brian G — Expression Therapeutics
- Study coordinator: Petrich, Brian G
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.